

# NEW SILKROUTES GROUP LIMITED AND ITS SUBSIDIARIES Registration Number: 199400571K

Condensed Interim Financial Statements For the six months Ended 31 December 2023

# **Table of Contents**

		Page
A.	Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
B.	Condensed Interim Statements of Financial Position	3
C.	Condensed Interim Statements of Changes in Equity	5
D.	Condensed Interim Consolidated Statement of Cash Flows	8
E.	Notes to the Condensed Interim Consolidated Financial Statements	10
F.	Other Information Required by Listing Rule Appendix 7.2	24

# CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	3 months ended 31 December 2023 Unaudited S\$'000	3 months ended 31 December 2022 Unaudited S\$'000	%	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000	%
Revenue Other income	4	3,479 211	10,121 146	(66) 45	5,970 524	19,007 409	(69) 28
Purchases of finished goods Changes in inventories of finished		(2,305)	(5,973)	(61)	(5,415)	(10,719)	(50)
goods		(647)	(11)	N.M.	183	(144)	N.M.
Employee benefits expense		(635)	(2,692)	(76) (100)	(1,440)	(5,559)	(74)
Amortisation of intangible assets Depreciation of property, plant and		-	(31)	(100)	-	(63)	(100)
equipment		(81)	(163)	(50)	(164)	(304)	(46)
Depreciation of right-of-use assets		(244)	(476)	(49)	(478)	(950)	(50)
Impairment loss on trade and other			(1)	(100)			(100)
receivables		(1,422)	(1) 781	(100) N.M.	(2,223)	(61) (101)	(100) 2,101
Other operating expenses Finance costs		(1,422) (68)	(383)	(82)	(2,223)	(604)	(47)
T manee costs		(00)	(303)	(02)	(323)	(004)	(47)
(Loss)/profit before taxation	6	(1,712)	1,318	N.M.	(3,366)	911	N.M.
Taxation	7		(108)	(100)	-	(186)	(100)
(Loss)/profit for the period		(1,712)	1,210	N.M.	(3,366)	725	N.M.

OTHER COMPREHENSIVE	3 months ended 31 December 2023 Unaudited S\$'000	3 months ended 31 December 2022 Unaudited S\$'000	%	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000	%
Other comprehensive (loss)/income:						
Item that may be reclassified subsequently to profit of loss:						
Foreign currency translation		(200)			<i></i>	
(loss)/gain on consolidation	(21)	(390)	N.M.	(187)	640	N.M.
Other comprehensive (loss)/income for the						
financial period, net of tax	(21)	(390)	N.M.	(187)	640	N.M.
Total comprehensive	(21)	(370)	11.101.	(107)	010	11.111.
(loss)/income for the						
financial period	(1,733)	820	N.M.	(3,553)	1,365	N.M.
(Loss)/profit attributable to:						
Owners of the Company	(1,650)	886	N.M.	(3,264)	69	N.M.
Non-controlling interests	(62)	324	N.M.	(102)	656	N.M.
=	(1,712)	1,210	N.M.	(3,366)	725	N.M.
Total comprehensive (loss)/income attributable to:						
Owners of the Company	(1,671)	496	N.M.	(3,451)	648	N.M.
Non-controlling interests	(62)	324	N.M.	(102)	717	N.M.
-	(1,733)	820	N.M.	(3,553)	1,365	N.M.
(Loss)/profit per share attributable to owners of the Company (cent)						
- Basic and diluted	(0.79)	0.42		(1.57)	0.03	

# CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONT'D)

# CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

		Grou 31 December 2023 Unaudited	p 30 June 2023 Audited	Compa 31 December 2023 Unaudited	ny 30 June 2023 Audited
	Note	S\$'000	S\$'000	S\$'000	S\$'000
ASSETS					
Non-current assets					
Property, plant and equipment		415	178	144	173
Intangible assets	9	-	-	-	-
Right-of-use assets		340	307	240	307
Subsidiaries		-	-	14,609	14,609
Total non-current assets		755	485	14,993	15,089
Current assets					
Inventories		36	36	-	-
Trade and other receivables		2,079	2,963	2,898	385
Prepayments		806	125	51	42
Cash and bank balances		7,673	3220	301	162
Fixed deposits		-	32	-	-
		10,594	6,376	3,250	589
Disposal group classified as held					
for sale		20,865	21,396	-	-
Total current assets		31,459	27,772	3,250	589
Total assets		32,214	28,257	18,243	15,678
EQUITY AND LIABILITIES					
EQUITY Share capital	10	120,784	120,784	120,784	120,784
Treasury shares	10	(1,182)	(1,182)	(1,182)	(1,182)
Other reserves		1,063	1,250	62	62
Accumulated losses		(156,083)	(152,819)	(154,999)	(153,146)
Equity attributable to equity holder		(100,000)	(,)		/
of the Company		(35,418)	(31,967)	(35,335)	(33,482)
Non-controlling interests		(1,615)	(1,513)	-	-
Total equity		(37,033)	(33,480)	(35,335)	(33,482)

# CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (CONT'D)

		Group		Company			
	Note	31 December 2023 Unaudited S\$'000	30 June 2023 Audited S\$'000	31 December 2023 Unaudited S\$'000	30 June 2023 Audited S\$'000		
LIABILITIES							
Non-current liabilities							
Lease liabilities	12	122	194	122	194		
Total non-current liabilities		122	194	122	194		
Current liabilities							
Trade and other payables		59,782	52,733	53,289	48,832		
Borrowings	12	1,865	2,058	-	-		
Lease liabilities	12	227	134	167	134		
Current income tax payable		13	13	-	-		
		61,887	54,938	53,456	48,966		
Liabilities directly associated with disposal group classified as held							
for sale		7,238	6,605	-			
Total current liabilities		69,125	61,543	53,456	48,966		
Total liabilities		69,247	61,737	53,578	49,160		
Total equity and liabilities		32,214	28,257	18,243	15,678		

# CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

<> Attributable to owners of the Company>										
	Share capital	Treasury shares	Foreign currency translation reserve	Capital reserve	Other reserves	Reserve of disposal group classified as held for sale	Accumulated losses	Total	Non- controlling interests	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	equity S\$'000
Group		- •							- •	* · · ·
Balance as at 1 July 2023	120,784	(1,182)	201	-	33	1,016	(152,819)	(31,967)	(1,513)	(33,480)
Loss for the financial period Other comprehensive income/(loss)	-	-	-	-	-	-	(3,264)	(3,264)	(102)	(3,366)
<ul> <li>Foreign currency translation differences</li> </ul>	-	-	13	_	-	(200)	-	(187)	-	(187)
Total comprehensive income/(loss) for the financial										
period	-	-	13	-	-	(200)	(3,264)	(3,451)	(102)	(3,553)
Balance as at 31 December 2023	120,784	(1,182)	214	-	33	816	(156,083)	(35,418)	(1,615)	(37,033)

# CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

	<		Attril	outable to o	wners of th	e Company		>		
	Share capital S\$'000	Treasury shares S\$'000	Foreign currency translation reserve S\$'000	Capital reserve S\$'000	Other reserves S\$'000	Reserve of disposal group classified as held for sale S\$'000	Accumulated losses S\$'000	Total S\$'000	Non- controlling interests S\$'000	Total equity S\$'000
Group	55 000	55 000	55 000	35 000	53 000	55 000	55 000	55 000	55 000	55 000
Balance as at 1 July 2022	120,784	(1,182)	799	62	-	(4,925)	(144,912)	(29,374)	429	(28,945)
Profit for the financial period Other comprehensive income - Foreign currency translation	-	-	-	-	-	-	69	69	656	725
differences	-	-	579	-	-	-	-	579	61	640
Total comprehensive income for the financial period	-	-	579	-	-	-	69	648	717	1,365
Contributions by and distributions to owners										
- Dividends	-	-	-	-	-	-	-	-	(564)	(564)
Transactions with owners in their own capacity as owners	-	-	_	-	-	-	-	-	(564)	(564)
Balance as at 31 December 2022	120,784	(1,182)	1,378	62	-	(4,925)	(144,843)	(28,726)	582	(28,144)

# CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

Company	Share capital S\$'000	Treasury shares S\$'000	Capital reserve S\$'000	Accumulated losses S\$'000	Total equity S\$'000
Balance as at 1 July 2023 Profit for the year, representing total comprehensive loss for	120,784	(1,182)	62	(153,146)	(33,482)
the financial period	-	-	-	(1,853)	(1,853)
Balance as at 31 December 2023	120,784	(1,182)	62	(154,999)	(35,335)
<b>Balance as at 1 July 2022</b> Profit for the year, representing	120,784	(1,182)	62	(142,256)	(22,592)
total comprehensive income for the financial period	-	-	-	766	766
Balance as at 31 December 2022	120,784	(1,182)	62	(141,490)	(21,826)

# CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

	Gro 6 months ended 31 December 2023 Unaudited S\$'000	oup 6 months ended 31 December 2022 Unaudited S\$'000
Cash flows from operating activities		011
(Loss)/profit before taxation:	(3,366)	911
Adjustments for:		
Amortisation of intangible assets	-	63
Depreciation of property, plant and equipment	164	304
Depreciation of right-of-use assets	478	950
Interest expense	323	604
Impairment losses recognised on trade and other		
receivables	-	61
Unrealised foreign exchange differences	486	(207)
Operating cash flows before working capital changes:	(1,915)	2,686
Changes in inventories	(183)	51
Changes in trade and other receivables	(273)	(3,167)
Changes in prepayments	(709)	(94)
Changes in trade and other payables	6,006	3,429
Cash generated from operations	2,926	2,905
Income tax paid	-	-
Net cash generated from operating activities	2,926	2,905
Cash flows from investing activities		
Advance received from disposal of subsidiary	5,589	_
Advance for the acquisition of subsidiary	(747)	-
Purchase of property, plant and equipment	(276)	(274)
Net cash generated from/(used in) investing activities	4,566	(274)

# CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS (CONT'D)

	Gro 6 months ended 31 December 2023 Unaudited S\$'000	oup 6 months ended 31 December 2022 Unaudited S\$'000
Cook flows from financing activities		
<b>Cash flows from financing activities</b> Dividends paid to the non-controlling interests of the		
subsidiaries	-	(564)
Interest paid	(323)	(326)
Proceeds from loans	1,900	-
Repayment of loans	(2,503)	(843)
Repayment of lease liabilities	(99)	(575)
Pledged fixed deposits	32	-
Repayment to a creditor	(2,818)	-
Net cash used in financing activities	(3,811)	(2,308)
Net increase in cash and cash equivalents	3,681	323
Cash and cash equivalents at beginning of financial period Exchange differences on translation of cash and	4,467	5,679
cash equivalents	(133)	(1,025)
Cash and cash equivalents at end of financial period	8,015	4,977
Cash and cash equivalents comprise the following:		
Cash and bank balances and fixed deposits	7,673	4,500
Disposal groups classified as held for sale	343	1,010
Less: Cash restricted in use	(1)	(1)
Less: Fixed deposits pledged	-	(532)
Cash and cash equivalents at end of financial period	8,015	4,977

# NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

# **1** Corporate information

New Silkroutes Group Limited (the "**Company**") (Co. Reg. No. 199400571K) is a limited liability company incorporated and domiciled in Singapore. The address of its registered office and principal place of business is at 456 Alexandra Road, #24-01 Fragrance Empire Building, Singapore 119962. The Company is listed on the Singapore Exchange Securities Trading Limited. These condensed interim consolidated financial statements as at and for the six months ended 31 December 2023 comprise the Company and its subsidiaries (collectively, the "**Group**").

The principal activities of the Company are that of an investment holding Company. The principal activities of the Group as at 31 December 2023 were:

- (a) Manufacture of non-woven fabric;
- (b) Management services and investment holding.

#### Proposed Restructuring Exercise

The Company on 9 January 2023 applied to the High Court of the Republic Singapore (the "**Court**") for moratorium protection pursuant to Section 64 of the Insolvency, Restructuring, and Dissolution Act 2018 ("**IRDA**"). On 6 February 2023, the Court granted the moratorium protection sought until 9 July 2023, which was subsequently extended to 9 October 2023, and further extended to 9 December 2023. The purpose of the moratorium is to facilitate the reorganisation of the liabilities and business of the Company and the Group, to preserve the value of the Group's core business and maintain a sustainable capital structure. During the moratorium, the Company worked with its advisors to formulate a "pre-packaged" scheme of arrangement pursuant to Section 71 of the IRDA which would benefit all its creditors at large (the "**Scheme**").

Following the proposal of the Scheme to its creditors, the Company applied to the Court for an order approving the Scheme and on 1 December 2023, the Court granted the orders sought, thereby approving the Scheme. The Ontario Whitewash Waiver (as defined in the announcement dated 24 October 2023) has also been granted by the Securities Industry Council subject to the conditions disclosed in the announcement.

The restructuring exercise is still ongoing as at the date of these financial statements.

# 2 Basis of preparation

The condensed interim financial statements are for the six months ended 31 December 2023 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last audited financial statements for the year ended 30 June 2023.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in SGD or S\$, which is the Company's functional currency and all values in the tables are rounded to the nearest thousand (S\$'000), except when otherwise indicated.

# 2 Basis of preparation (cont'd)

#### 2.1 New and amended standards adopted by the Group

A number of amendments to Standards has become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

# 2.2 Use of judgements and estimates

#### Critical judgements in applying the entity's accounting policies

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 30 June 2023.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

#### Going concern assumptions

During the financial period ended 31 December 2023, the Group reported net loss of \$\$3,366,000 (31 December 2022: net profit of \$\$725,000) and the Company reported a net loss of \$\$1,367,000 (31 December 2022: net profit of \$\$766,000). The Group's and the Company's current liabilities exceeded the current assets by \$\$37,666,000 (30 June 2023: \$\$33,771,000) and \$\$50,206,000 (30 June 2023: \$\$48,377,000) respectively. These conditions indicate the existence of material uncertainties that may cast significant doubts about the Group's and the Company's abilities to continue as going concerns.

The Directors of the Company are of the view that the going concern assumption is appropriate for the preparation of these financial statements based on the following assessments:

(i) On 9 January 2023, the Company applied to the Court for moratorium protection pursuant to Section 64 of the IRDA. On 6 February 2023, the Court granted a moratorium until 9 July 2023, which was subsequently extended to 9 October 2023, and thereafter until 9 December 2023. The purpose of the moratorium was to facilitate the reorganisation of the liabilities and the business of the Company and the Group, and to maintain a sustainable capital structure.

During the moratorium, the Company worked with its advisors to formulate the Scheme. The scheme document, comprising, among other things, the Scheme and the Explanatory Statement, was sent to the creditors on 6 September 2023. Under the Scheme, each creditor (save for 3 creditors that are related to the Company) ("**Class A Scheme Creditor**") was given the option to elect between (a) converting approximately 1% of its debt into equity in the Company ("**Equity Option**"), or (b) receiving a cash payment equivalent to up to 6% of its debt ("**Cash Option**"), in full and final settlement of its debt. In addition, any surplus cash that the Company receives from the disposal of Shanghai Fengwei Garment Accessory Co., Ltd. ("**Shanghai Fengwei**") would be distributed *pari passu* to the Class A Scheme Creditors. The objective of the Scheme is to restructure the liabilities of the Company by reducing the Company's debt to a sustainable level, and thereby allow the Company to continue as a going concern.

# 2 Basis of preparation (cont'd)

# 2.2 Use of judgements and estimates (cont'd)

#### Critical judgements in applying the entity's accounting policies (cont'd)

Going concern assumption (cont'd)

The Scheme was approved by all the Class A Scheme Creditors that voted on the Scheme. On 20 October 2023, the Company consequently applied to the Court to approve the Scheme pursuant to Section 71(1) of the IRDA. On 1 December 2023, the Court sanctioned the Scheme.

- (ii) The Scheme is subject to several conditions precedent being met prior to 1 December 2024, including obtaining the approval of the SGX-ST for the resumption of trading of the Company's shares on the Mainboard of the SGX-ST. The Company has made an application to the SGX-ST for the resumption of trading of its shares. Pursuant to the SGX-ST's outcome letter received on 11 September 2024, the Company is required to resubmit a revised trading resumption proposal by 31 December 2024, which the Company is addressing.
- (iii) 2810198 Ontario ("Ontario"), the largest creditor of the Group, has elected for the Equity Option. In the event that the Scheme is implemented, Ontario is expected to hold 70% of the shares of the Company. Ontario has plans to use the Company as a vehicle to hold various businesses. The future value of the Company will be underpinned by the value of the businesses and investments that Ontario injects into the Company.
- (iv) In the meantime, Ontario has provided the Company with rescue financing. On 14 September 2023, the Company and Ontario executed an agreement for Ontario to provide rescue financing of up to \$\$5.9 million to the Company, to fund (i) the Company's working capital requirements, (ii) the Company's restructuring costs, and (iii) the implementation of the Cash Option under the Scheme. Following the Company's application to the Court pursuant to Section 67(1) of the IRDA, the debt arising from Ontario's rescue financing has been conferred priority over all the preferential debts specified in Section 203(1)(a) to (i) of the IRDA and all other unsecured debts.

The Directors are of the opinion that the above would allow the Group to restructure its operations and enable the Group and the Company to pay their debts as and when they fall due.

For these reasons, the financial statements have been prepared on the assumptions that the Group and Company will continue as going concerns. The financial statements did not include any adjustments that may result in the event that the Group and Company are unable to continue in operational existence for the foreseeable future, the Group and Company may be unable to realise its assets and discharge its liabilities in the normal course of business and adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are currently recorded in the statements of financial position. In addition, the Group and Company may have to provide for further liabilities that might arise, and to reclassify non-current assets and liabilities as current assets and liabilities. No such adjustments have been made in the financial statements.

# 2 Basis of preparation (cont'd)

# 2.2 Use of judgements and estimates (cont'd)

#### Critical judgements in applying the entity's accounting policies (cont'd)

#### Control over Shanghai Fengwei Garment Accessory Co., Ltd. ("Shanghai Fengwei")

Pursuant to the Management Agreement, the Company assigned the management rights and the profits of Shanghai Fengwei during the period from 1 January 2020 to 31 December 2021 to the Entity. All post-tax profits or losses during the aforesaid period, whether in excess of or less than the Consideration, shall be attributable to or borne by the Entity. In return, the Entity would retain the net profit or loss after tax generated by Shanghai Fengwei for 2020 and 2021.

The directors of the Company made an assessment that Shanghai Fengwei's management continues to manage the operations and business activities of Shanghai Fengwei and that the Group has control over Shanghai Fengwei in accordance with the definition of control and the related guidance set out in SFRS(I) 10 Consolidated Financial Statements. Accordingly, Shanghai Fengwei remains a subsidiary of the Group.

#### Key sources of estimation uncertainty

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial period are included in the following notes:

#### Impairment of trade and other receivables

The Group has applied the simplified approach within SFRS(I) 9, based on lifetime ECL, in determining the loss allowance on trade receivables at the end of each reporting period.

The Group determined the ECL of trade receivables by categorising them based on days past due for groupings of various customer segments that have similar loss patterns. The ECL rates for each category of the debtors are estimated based on historical credit loss experience adjusted as appropriate to reflect current condition and forward-looking information which is based on assumptions and forecasts of future economic conditions.

As the calculation of loss allowance on trade receivables and contract assets is subject to assumptions and forecasts, any changes to these estimations will affect the amounts of loss allowance recognised and the carrying amounts of trade receivables and contract assets.

#### Impairment test for cash-generating unit containing goodwill and intangibles

A cash-generating unit ("CGU") to which goodwill has been allocated shall be tested for impairment annually, and whenever there is an indication that the unit may be impaired, by comparing the carrying amount of the CGU, including the goodwill, with the recoverable amount of the CGU. The recoverable amount is the higher of the CGU's fair value less costs of disposal and its value in use. Where the recoverable amount of the CGU is less than its carrying amount, such impairment loss is recognised in profit or loss.

# 2 Basis of preparation (cont'd)

# 2.2 Use of judgements and estimates (cont'd)

# Key sources of estimation uncertainty (cont'd)

Significant judgement and estimates by management are required in assessing: (i) whether the carrying amount of the CGU can be supported by its market value based on comparable assets or the net present value of future cash flows which are estimated based upon the continued use of the assets in the business; and (ii) the appropriate key assumptions to be applied in preparing cash flow projections including whether these cash flow projections are extrapolated using a suitable growth rate and then discounted using an appropriate discount rate. Changing the assumptions selected by management to determine the level of impairment, including the growth rate and discount rate assumptions in the cash flow projections, could materially affect the net present value used in the impairment test and as a result may potentially affect the Group's results. The carrying amounts of the Group's intangible assets, including goodwill, at the end of the reporting period, and the basis and assumptions used to determine the recoverable amount of the CGU, are disclosed in Note 9.

# Impairment of investment in subsidiaries

At the end of each reporting period, the Company assesses whether there are any indications of impairment for investment in subsidiaries. The Company also assesses whether there is any indication that an impairment loss recognised in prior periods for investment in subsidiaries may no longer exist or may have decreased.

If any such indication exists, the Company estimates the recoverable amount of that asset. An impairment loss exists when the carrying value of an asset exceeds its recoverable amount, which is the higher of its fair value less costs to sell and its value in use. An impairment loss recognised in prior periods shall be reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised.

# Estimation of financial guarantee liabilities

Financial guarantees are financial instruments issued by the Company that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payments when due in accordance with the terms of a debt instrument.

Financial guarantee contract liabilities are initially measured at their fair values. Subsequently, they are measured at the higher of the loss allowance determined in accordance with SFRS (I) 9 and the amount initially recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of SFRS (I) 15.

# **3** Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

#### 4 Segment and revenue information

For management purposes, the Group is organised into business units based on their products and services, and has three reportable operating segments as follows:

- Healthcare owns and operates clinics in Singapore providing complementary integrative therapies, runs employee healthcare benefits programmes, offers systems integration services to hospitals and healthcare facilities, owns and operates clinics in Singapore providing dental services, and distributes dental and medical supplies, and manufacturing of healthcare consumables.
- Others general corporate activities and others

The Group's executive directors monitor the operating results of its operating segments for the purpose of making decisions about resource allocation and performance assessment.

Information regarding the results of each reportable segment is included in the following table. Performance is measured based on segment profit/(loss) before taxation, as included in the internal management reports that are regularly reviewed by the Group's executive directors. Segment profit/(loss) is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

1 July 2023 to 31 December 2023	Healthcare Unaudited S\$'000	Others Unaudited	Elimination Unaudited	Per consolidated financial statements Unaudited S\$'000
Segment revenue - Sales to external customers	5,824	146	-	5,970
<ul> <li>Segment results</li> <li>Other income</li> <li>Depreciation of property, plant and equipment</li> <li>Depreciation of rights of use search</li> </ul>	417 (125)	107 (39)	-	524 (164)
<ul> <li>Depreciation of rights-of-use assets</li> <li>Finance costs</li> <li>Segment loss</li> </ul>	(391) (87) (1,501)	(87) (236) (1,865)		(478) (323) (3,366)
Segment assets and liabilities - Segment assets - Segment liabilities	15,403 9,700	54,336 77,329	(37,525) (17,782)	32,214 69,247

#### **4.1 Reportable segments**

# 4 Segment and revenue information (cont'd)

# 4.1 Reportable segments (cont'd)

1 July 2022 to 31 December 2022	Healthcare Unaudited S\$'000	Per consolidated financial statements Unaudited S\$'000
Segment revenue - Sales to external customers	19,007	19,007
<ul> <li>Segment results</li> <li>Other income</li> <li>Amortisation of intangible assets</li> <li>Depreciation of property, plant and equipment</li> <li>Depreciation of rights-of-use assets</li> <li>Finance costs</li> <li>Segment profit</li> </ul>	409 (63) (304) (950) (604) 725	409 (63) (304) (950) (604) 725
Segment assets and liabilities - Segment assets - Segment liabilities	45,136 73,280	45,136 73,280

\* Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

# 4.2 Disaggregation of revenue

	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000
Healthcare products	5,824	10,316
Healthcare services	-	8,691
Others	146	-
	5,970	19,007

# 4 Segment and revenue information (cont'd)

# 4.2 Disaggregation of revenue (cont'd)

# **Geographical information:**

	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000
China	5,970	10,316
Singapore	-	8,691
	5,970	19,007

# 5 Financial assets and financial liabilities

# 5.1 Categories of financial instruments

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 December 2023 and 30 June 2023:

	Grou	up	Company	
	31 December 2023 Unaudited S\$'000	30 June 2023 Audited S\$'000	31 December 2023 Unaudited S\$'000	30 June 2023 Audited S\$'000
<b>Financial assets</b> Financial assets at amortised cost	18,265	14,476	3,199	547
<b>Financial liabilities</b> Lease liabilities Financial liabilities at amortised	349	328	289	328
cost	68,885	61,396	53,289	48,832

# 6 (Loss)/profit before taxation

# 6.1 Significant items

<u>Group</u>	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000
Impairment loss recognised on trade and other receivables	-	61

# 6.2 Related party transactions

Other than as disclosed elsewhere in the interim financial statements, the following related party transactions took place between the Group and related parties during the financial period on terms agreed by the parties concerned:

	6 months ended 31 December 2023 Unaudited S\$'000	6 months ended 31 December 2022 Unaudited S\$'000
Group		
Interest expense Lease payments (rental)	-	109 356

# 7 Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

Group	6 mont ended 31 Decen 2023 Unaudit S\$'00	l nber ted	6 months ended 31 December 2022 Unaudited S\$'000
Current taxation: - Current period - 186 - Changes in estimates related to prior years	eriod in estimates related to	-	186
- 186 Deferred taxation:	vation:	-	186
- Origination and reversal of temporary differences	on and reversal of	-	-
- 186		-	186

# 8 Net asset value

	Grou	ъ	Company		
	31 December 2023 Unaudited	30 June 2023 Audited	31 December 2023 Unaudited	30 June 2023 Audited	
Net asset value per ordinary share (cent)	(16.99)	(15.33)	(16.95)	(16.06)	

# 9 Intangible assets

Group	Goodwill S\$'000	Customer relationship S\$'000	CMS Development costs S\$'000	Service right S\$'000	Trademark S\$'000	Total S\$'000
Re-presented	54 000	50 000	50 000	5000	50000	54 000
Cost:						
Balance at 1 July 2022	7,439	375	2,115	122	452	10,503
Additions	314	-	-	-	-	314
Reclassified from disposal group held for sales	2,110	-	-	-	-	2,110
Reclassified to disposal group held for sales	(7,439)	(375)	-	-	(452)	(8,266)
Written off	-	-	(2,115)	(122)	-	(2,237)
Currency translation differences	7	-	-	-	-	7
Balance at 30 June 2023, 1 July 2023 and 31 December 2023	2,431	-				2,431
Accumulated amortisation:						
Balance at 1 July 2022	-	141	2,115	122	316	2,694
Amortisation	-	36	-	-	90	126
Impairment charge	2,431	-	-	-	-	2,431
Reclassified to disposal group held for sales Written off	-	(179)	-	-	(406)	(585)
	-	- 2	(2,115)	(122)	-	(2,237)
Currency translation differences	-	2	-	-	-	2
Balance at 30 June 2023, 1 July 2023 and 31 December 2023	2,431	-	-	-	-	2,431
Carrying amount: Balance at 31 December 2023	-	_	-	-	-	-
Balance at 30 June 2023	-	-	_	-	_	

# 9 Intangible assets (cont'd)

#### Impairment testing for a cash-generating unit containing goodwill

Goodwill that has an indefinite useful life are not subject to amortisation and are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired. No impairment indicators were identified as at 31 December 2023 based on each CGU's business performance. The Group performed its annual impairment test in June 2023. The key assumptions used to determine the recoverable amount for the CGU were disclosed in the last audited financial statements for the year ended 30 June 2023. The Group tests goodwill annually for impairment or more frequently if there are indicators that goodwill might be impaired.

# 10 Share capital

	31 December 2023		30 June	2023
	Number of shares	Amount S\$'000 <b>Unaudited</b>	Number of shares	Amount S\$'000 Audited
Group and Company				
Issued and fully paid with no par value At beginning and end of interim period	211,908,869	120,784	211,908,869	120,784

The number of issued shares excluding treasury shares as at the end of the interim period was 208,464,669 (30 June 2023: 208,464,669).

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at shareholders' meetings. All shares rank equally with regard to the Company's residual assets.

The Company's subsidiaries do not hold any shares in the Company as of 31 December 2023 and 30 June 2023.

#### **11** Treasury shares

	31 December 2023		<b>30 Jun</b>	e 2023
	Number of shares	Amount S\$'000 <b>Unaudited</b>	Number of shares	Amount S\$'000 Audited
Group and Company				
<i>Issued and fully paid with no par value</i> At beginning and end of interim period	3,444,200	(1,182)	3,444,200	(1,182)

# **12 Borrowings**

	Group		
	31 December 2023 Unaudited S\$'000	30 June 2023 Audited S\$'000	
Amount repayable within one year or on demand Bank loans, secured Lease liabilities, unsecured	1,865 227	2,058 134	
Amount repayable after one year Bank loans, secured Lease liabilities, unsecured	122	- 194	
	2,214	2,386	

Loans from financial institutions are secured by the following:

- i. fixed deposits of the Group;
- ii. corporate guarantees by the Company and related parties;
- iii. charges over shares of certain subsidiaries of the Company;
- iv. personal guarantee(s) from a director of the Company and a former director of the Company and/or directors of subsidiaries;
- v. pledge over a director's land;
- vi. fixed and floating charge on all assets and undertakings of a subsidiary; and/or
- vii. certain property and equipment.

# 13 Subsequent events

# Disposal of Shanghai Fengwei

The Company refers to its announcements dated 28 April 2023, 21 July 2023 and 24 June 2024 in relation to the disposal of 100% of the equity of Shanghai Fengwei, which has been completed in FY2024.

# Proposed Restructuring Exercise

The Company on 9 January 2023 applied to the Court for moratorium protection pursuant to Section 64 of the IRDA. On 6 February 2023, the Court granted the moratorium protection sought until 9 July 2023, which was subsequently extended to 9 October 2023, and further extended to 9 December 2023. The purpose of the moratorium is to facilitate the reorganisation of the liabilities and business of the Company and the Group, to preserve the value of the Group's core business and maintain a sustainable capital structure. During the moratorium, the Company worked with its advisors to formulate the Scheme.

Following the proposal of the Scheme to its creditors, the Company applied to the Court for an order approving the Scheme and on 1 December 2023, the Court granted the orders sought, thereby approving the Scheme. The Ontario Whitewash Waiver (as defined in the announcement dated 23 October 2023) has also been granted by the Securities Industry Council subject to the conditions disclosed in the announcement.

The restructuring exercise is still ongoing as at the date of these financial statements.

# 13 Subsequent events (cont'd)

# Voluntary Liquidation of Healthsciences International Pte. Ltd. ("HSI") and HSI Dental Pte. Ltd. ("HSID")

The Company refers to its announcement dated 29 September 2023 in relation to voluntary liquidation of HSI and HSID. HSI and HSID have been placed into creditors' voluntary liquidation on 29 September 2023, which is ongoing.

#### Acquisition of Tianjin Zhoushun Logistics Co., Ltd.

The Company refers to its announcements dated 18 September 2023, 10 October 2023 and 25 June 2024 in relation to the acquisition of 100% of the equity of Tianjin Zhoushun Logistics Co., Ltd., which has been completed in FY2024.

#### Striking off of HSI Asia Pte. Ltd., HSI Specialists Pte. Ltd. and HSI Cardiology Pte. Ltd.

The Company refers to its announcement dated 15 April 2024 in relation to the striking off of HSI Asia Pte. Ltd., HSI Specialists Pte. Ltd. and HSI Cardiology Pte. Ltd.

# **OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2**

# 1. Review

The condensed consolidated statement of financial position of New Silkroutes Group Limited and its subsidiaries as of 31 December 2023 and the related condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period ended and certain explanatory notes have not been audited or reviewed.

# Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion: -

#### (a) Updates on efforts taken to resolve each outstanding audit issue

The auditors have issued a disclaimer of opinion on the Group's financial statements for the financial year ended 30 June 2023 due to:

- i. Going concern assumptions
- ii. Opening balances as at 1 July 2022 for the financial year ended 30 June 2022 whose report dated 31 August 2023 contained a disclaimer of opinion.
- iii. Financial impact related to independent review report and notice of compliance issued by Singapore Exchange Regulation ("SGX RegCo")
- iv. Financial guarantees and provisions in respect of banking facilities extended to its subsidiaries.
- v. Classification and appropriateness of the disposal group classified as held for sale and discontinued operation
- vi. Appropriateness of accounting for disposals of subsidiaries
- vii. Appropriateness of accounting for disposal of businesses
- viii. Appropriateness of accounting for acquisition of Hidderton Limited and its subsidiaries
- ix. Appropriateness of the impairment loss recognised for the investments in subsidiaries

Please refer to page 44 - 49 of the Company's Annual Report for the financial year ended 30 June 2023 for more information on these outstanding audit issues.

The Company will follow up with the appropriate accounting treatment on these outstanding audit issues.

# (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

The Board confirms that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

# 2. Review of performance of the Group

#### **Income Statement Review**

# Second Quarter Ended 31 December 2023 ("2Q24") against Second Quarter Ended 31 December 2022 ("2Q23")

Group revenue decreased to S\$3.48 million in 2Q24 compared to S\$10.12 million in 2Q23. This is due to 1) the disposal of medical and dental clinics in last financial year and 2) new acquired subsidiaries have not yet generated revenue.

Other income increased to S\$0.21 million in 2Q24 when compared to S\$0.15 million in 2Q23 mainly due to other income contributed by Shanghai Fengwei and interest income from a China subsidiary in 2Q23.

Purchases of finished goods decreased to S\$2.31 million in 2Q24 from S\$5.97 million in 2Q23. The decrease is in line with the decrease in revenue.

Employee benefits expense decreased to S\$0.64 million in 2Q24 when compared to S\$2.69 million in 2Q23 mainly due to disposal of medical and dental clinics in last financial year.

Other operating expenses increased to S\$1.42 million in 2Q24 from (S\$0.78) million in 2Q23 mainly due to the exchange loss for the financial period instead of exchange gain in last financial period.

Finance costs decreased to S\$0.07 million in 2Q24 from S\$0.38 million in 2Q23 mainly due to lower borrowings for the financial period.

# Half Year Ended 31 December 2023 ("1H24") against Half Year Ended 31 December 2022 ("1H23")

Group revenue decreased to S\$5.97 million in 1H24 compared to S\$19.01 million in 1H23. This is due to 1) the disposal of medical and dental clinics in last financial year and 2) new acquired subsidiaries have not yet generated revenue.

Other income increased to S\$0.52 million in 1H24 when compared to S\$0.41 million in 1H23 mainly due to other income contributed by Shanghai Fengwei and interest income from a China subsidiary in 1H24.

Purchases of finished goods decreased to S\$5.42 million in 1H24 from S\$10.72 million in 1H23. The decrease is in line with the decrease in revenue.

Employee benefits expense decreased to S\$1.44 million in 1H24 when compared to S\$5.56 million in 1H23 mainly due to disposal of medical and dental clinics in last financial year.

Other operating expenses increased to S\$2.22 million in 1H24 from S\$0.10 million in 1H23 mainly due to the exchange loss for the financial period instead of exchange gain in last financial period.

Finance costs decreased to S\$0.32 million in 1H24 from S\$0.60 million in 1H23 mainly due to lower borrowings for the financial period.

#### **Financial Position Review**

Property, plant and equipment increased to S\$0.42 million as at 31 December 2023 compared to S\$0.18 million as at 30 June 2023, mainly due to purchase of property, plant and equipment.

# 2. Review of performance of the Group (cont'd)

# Financial Position Review (cont'd)

Right-of-use assets increased to S\$0.34 million as at 31 December 2023 from S\$0.31 million as at 30 June 2023 due to sign-up of a new office space in China. As such, the corresponding lease liabilities increased to S\$0.35 million as at 31 December 2023 from S\$0.33 million as at 30 June 2023.

Trade and other receivables decreased to S\$2.08 million as at 31 December 2023 from S\$2.96 million as at 30 June 2023 mainly due to receipt of one debtor.

Trade and other payables increased to S\$59.78 million as at 31 December 2023 from S\$52.73 million as at 30 June 2023 mainly due to receipt of advance from disposal of a subsidiary.

Current borrowings decreased to S\$1.87 million as at 31 December 2023 from S\$2.06 million as at 30 June 2023 due to the repayment of loans.

#### **Cash Flow Statement Review**

Net cash flows generated from operating activities of S\$2.93 million in 1H24 mainly due to losses incurred and change in working capital during the financial period.

Net cash flows generated from investing activities amounted to S\$4.57 million were mainly due to receipt of advance for disposal of a subsidiary.

Net cash flows used in financing activities of S\$3.81 million were mostly used to repay loans, one creditor and lease liabilities.

# **3.** Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast has been issued for the current financial reporting period.

# 4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

As of the report's release date, the Company has made substantial progress in its restructuring initiatives, successfully divested our interests in all HSIM practices and all Traditional Chinese Medicine practices, and has disposed of all the Group's practices held by HSID. Furthermore, Shanghai Fengwei has been disposed of in FY2024. The expeditious and efficient divestiture of these assets, optimising their value and mitigating liabilities, is a testament to the Group's commitment to prudent management.

The Group on 15 September 2023 has proposed the acquisition of Tianjin Zhoushun Logistics Co., which indirectly holds 59% of Hequ Yuanyang Industrial Co., Ltd. primarily engaged in the business of coal storage and sales and general cargo loading and unloading. Please refer to our official public announcements for comprehensive details. As such, as at the date of this announcement, the Company has prepared this set of financial results for the financial period up to 31 December 2023 on the assumption that the Company and/or Group is able to continue as a going concern. The Company will make appropriate announcements accordingly when more information is available.

Please refer to Note 13 (Subsequent Events) above for further information on further factors and events that may affect the Group.

# 5. Dividend information

(a) <u>Current financial period reported on</u> Any dividend recommended for the current financial period reported on?

None.

(b) <u>Corresponding period of the immediate preceding financial year</u> Any dividend declared for the corresponding period of the immediately preceding financial year?

None.

(c) <u>Date payable</u>

Not applicable.

(d) Book closure date

Not applicable.

(e) If no dividend has been declared/recommend, a statement to the effect and the reasons for the decision

No dividend has been declared or recommend for the period ended 31 December 2023 due to accumulated losses of the Company.

# 6. Interested person transactions

The Group does not have a general mandate for interested person transactions during the reporting period.

# 7. Disclosure on Acquisitions and Realisations of Shares pursuant to Rule 706A of the Listing Manual

During the period ended 31 December 2023, there were no acquisitions or realisations of shares resulting in a company becoming or ceasing to be a subsidiary or associated company of the Company, or resulting in the Company increasing or reducing its shareholding percentage in a subsidiary or associated company except as disclosed below:

Incorporation of Heilongjiang Xingzhou Port Agricultural Development Co., Ltd.

The Company refers to its announcement dated 7 June 2024 in relation to the incorporation of Heilongjiang Xingzhou Port Agricultural Development Co., Ltd., which was completed on 31 October 2023.

Please refer to Note 13 (Subsequent Events) above for subsequent acquisitions and disposals of shares carried out by the Group.

# 8. Negative assurance confirmation on the interim financial results pursuant to Rule 705(5) of the Listing Manual

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the six months ended 31 December 2023 to be false or misleading in any material respect.

#### On behalf of the Board of Directors

Darrell Lim Chee Lek Independent Non-Executive Chairman Chua Siong Kiat Independent Non-Executive Director

# 9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1)

The Company has received undertaking from all its directors and executive officers in the format as set out in Appendix 7.7 under Rule 720(1) of the Listing Manual of the SGX-ST.

#### **BY ORDER OF THE BOARD**

Mr. Han Binke Executive Director and CEO 19 September 2024